Federal Register / Vol. 88, No. 160 / Monday, August 21, 2023 / Notices 56847 

Bethesda, MD 20892, 240–276–6340, grayp@

mail.nih.gov. 

Any interested person may file written 

comments with the committee by forwarding 

the statement to the Contact Person listed on 

this notice. The statement should include the 

name, address, telephone number and when 

applicable, the business or professional 

affiliation of the interested person. 

Information is also available on the 

Institute’s/Center’s home page: NCAB: 

https://deainfo.nci.nih.gov/advisory/ncab/ 

ncabmeetings.htm, where an agenda, 

instructions for accessing the virtual NCAB 

meetings, and any additional information for 

the meetings will be posted when available. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.392, Cancer Construction; 

93.393, Cancer Cause and Prevention 

Research; 93.394, Cancer Detection and 

Diagnosis Research; 93.395, Cancer 

Treatment Research; 93.396, Cancer Biology 

Research; 93.397, Cancer Centers Support; 

93.398, Cancer Research Manpower; 93.399, 

Cancer Control, National Institutes of Health, 

HHS) 

Dated: August 16, 2023. 

Melanie J. Pantoja, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2023–17914 Filed 8–18–23; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute on Drug Abuse; 

Notice of Meeting 

Pursuant to section 1009 of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of a 

meeting of the National Advisory 

Council on Drug Abuse. 

This will be a hybrid meeting held inperson and virtually and will be open to 

the public, as indicated below, with 

attendance limited to space available. 

Individuals who plan to attend inperson or view the virtual meeting and 

need special assistance such as sign 

language interpretation or other 

reasonable accommodations, should 

notify Dr. Gillian Acca via email at 

gillian.acca@nih.gov five days in 

advance of the meeting. The open 

session of the meeting can be accessed 

from the NIH Videocast at the following 

link: https://videocast.nih.gov/. 

A portion of the meeting will be 

closed to the public in accordance with 

the provisions set forth in sections 

552b(c)(4) and 552b(c)(6), title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Advisory 

Council on Drug Abuse. 

Date: September 12, 2023. 

Closed: 10:30 a.m. to 11:45 a.m. 

Agenda: To review and evaluate grant 

applications. 

Open: 12:45 p.m. to 5:00 p.m. 

Agenda: Presentations and other business 

of the Council. 

Place: Neuroscience Center, Conference 

Room 1155/1145, National Institutes of 

Health, 6001 Executive Boulevard, Rockville, 

MD 20852 (Hybrid Meeting). 

Contact Person: Susan R.B. Weiss, Ph.D., 

Director, Division of Extramural Research, 

Office of the Director, National Institute on 

Drug Abuse, NIH, Three White Flint North, 

RM 09D08, 11601 Landsdown Street, 

Bethesda, MD 20852, 301–443–6480, sweiss@

nida.nih.gov. 

Contact Person: Gillian Acca, Ph.D., Health 

Science Policy Analyst, Division of 

Extramural Research, Office of Extramural 

Policy, National Institute on Drug Abuse, 

NIH, Three White Flint North, RM 09C70, 

11601 Landsdown Street, Bethesda, MD 

20852, 301–827–5863, gillian.acca@nih.gov. 

Any interested person may file written 

comments with the committee by forwarding 

the statement to Dr. Gillian Acca via email 

at gillian.acca@nih.gov. The statement 

should include the name, address, telephone 

number and when applicable, the business or 

professional affiliation of the interested 

person. 

In the interest of security, NIH has 

procedures at https://www.nih.gov/aboutnih/visitor-information/campus-accesssecurity for entrance into on-campus and offcampus facilities. All visitor vehicles, 

including taxicabs, hotel, and airport shuttles 

will be inspected before being allowed on 

campus. Visitors attending a meeting on 

campus or at an off-campus federal facility 

will be asked to show one form of 

identification (for example, a governmentissued photo ID, driver’s license, or passport) 

and to state the purpose of their visit. 

Information is also available on the 

Institute’s/Center’s home page: 

www.drugabuse.gov/NACDA/ 

NACDAHome.html, where an agenda and 

any additional information for the meeting 

will be posted when available. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.277, Drug Abuse Scientist 

Development Award for Clinicians, Scientist 

Development Awards, and Research Scientist 

Awards; 93.278, Drug Abuse National 

Research Service Awards for Research 

Training; 93.279, Drug Abuse and Addiction 

Research Programs, National Institutes of 

Health, HHS) 

Dated: August 15, 2023. 

Tyeshia M. Roberson-Curtis, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2023–17889 Filed 8–18–23; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Eunice Kennedy Shriver National 

Institute of Child Health and Human 

Development; Notice of Closed 

Meetings 

Pursuant to section 1009 of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meetings. 

The meetings will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: Eunice Kennedy 

Shriver National Institute of Child Health 

and Human Development Initial Review 

Group Pediatrics Study Section. 

Date: October 12, 2023. 

Time: 11:00 a.m. to 5:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, Eunice 

Kennedy Shriver National Institute of Child 

Health and Human Development, 6710B 

Rockledge Drive, Room 2140 Bethesda, MD 

20892 (Virtual Meeting). 

Contact Person: Joanna Kubler-Kielb, 

Ph.D., Scientific Review Officer, Scientific 

Review Branch, Eunice Kennedy Shriver 

National Institute of Child Health and 

Human Development, National Institutes of 

Health, 6710B Rockledge Drive, Room 2140, 

Bethesda, MD 20892, (301) 435–6916 kielbj@

mail.nih.gov. 

Name of Committee: Eunice Kennedy 

Shriver National Institute of Child Health 

and Human Development Initial Review 

Group Health, Behavior, and Context Study 

Section. 

Date: October 16, 2023. 

Time: 9:00 a.m. to 5:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, Eunice 

Kennedy Shriver National Institute of Child 

Health and Human Development, 6710B 

Rockledge Drive, Room 2137C Bethesda, MD 

20892 (Virtual Meeting). 

Contact Person: Kimberly L. Houston, 

M.D., Scientific Review Officer, Scientific 

Review Branch, Eunice Kennedy Shriver 

National Institute of Child Health and 

Human Development, National Institutes of 

Health, 6710B Rockledge Drive, Room 2137C, 

Bethesda, MD 20892, (301) 827–4902, 

kimberly.houston@nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.865, Research for Mothers 

and Children, National Institutes of Health, 

HHS) 


ddrumheller on DSK120RN23PROD with NOTICES1